Literature DB >> 15607371

Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.

Eugenia Flores-Figueroa1, Rosa Maria Arana-Trejo, Guillermo Gutiérrez-Espíndola, Adrián Pérez-Cabrera, Hector Mayani.   

Abstract

Bone marrow-derived mesenchymal stem cells (MSC) have been defined as primitive, undifferentiated cells, capable of self-renewal and with the ability to give rise to different cell lineages, including adipocytes, osteocytes, fibroblasts, chondrocytes, and myoblasts. MSC are key components of the hematopoietic microenvironment. Several studies, including some from our own group, suggest that important quantitative and functional alterations are present in the stroma of patients with myelodysplasia (MDS). However, in most of such studies the stroma has been analyzed as a complex network of different cell types and molecules, thus it has been difficult to identify and characterize the cell(s) type(s) that is (are) altered in MDS. In the present study, we have focused on the biological characterization of MSC from MDS. As a first approach, we have quantified their numbers in bone marrow, and have worked on their phenotypic (morphology and immunophenotype) and cytogenetic properties. MSC were obtained by a negative selection procedure and cultured in a MSC liquid culture medium. In terms of morphology, as well as the expression of certain cell markers, no differences were observed between MSC from MDS patients and those derived from normal marrow. In both cases, MSC expressed CD29, CD90, CD105 and Prolyl-4-hydroxylase; in contrast, they did not express CD14, CD34, CD68, or alkaline phosphatase. Interestingly, in five out of nine MDS patients, MSC developed in culture showed cytogenetic abnormalities, usually involving the loss of chromosomal material. All those five cases also showed cytogenetic abnormalities in their hematopoietic cells. Interestingly, in some cases there was a complete lack of overlap between the karyotypes of hematopoietic cells and MSC. To the best of our knowledge, the present study is the first in which a pure population of MSC from MDS patients is analyzed in terms of their whole karyotype and demonstrates that in a significant proportion of patients, MSC are cytogenetically abnormal. Although the reason of this is still unclear, such alterations may have an impact on the physiology of these cells. Further studies are needed to assess the functional integrity of MDS-derived MSC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607371     DOI: 10.1016/j.leukres.2004.06.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  50 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

2.  The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS.

Authors:  Aravind Ramakrishnan; Norihiro Awaya; Eileen Bryant; Beverly Torok-Storb
Journal:  Blood       Date:  2006-07-15       Impact factor: 22.113

Review 3.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

4.  Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma.

Authors:  Jennifer L Chan; Katherine C Tang; Anoop P Patel; Larissa M Bonilla; Nicola Pierobon; Nicholas M Ponzio; Pranela Rameshwar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

Review 5.  Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes.

Authors:  Jingya Wang; Zhijian Xiao
Journal:  Stem Cell Investig       Date:  2014-08-21

Review 6.  Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation.

Authors:  Charalampos Pontikoglou; Frédéric Deschaseaux; Luc Sensebé; Helen A Papadaki
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

7.  Adult rat bone marrow stromal cells differentiate into Schwann cell-like cells in vitro.

Authors:  WeiWei Lin; Xue Chen; XiaoDong Wang; Jie Liu; XiaoSong Gu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-11-06       Impact factor: 2.416

8.  Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia.

Authors:  Keisuke Shirai; Yasuhiko Sera; William Bulkeley; Meenal Mehrotra; Omar Moussa; Amanda C LaRue; Dennis K Watson; Robert K Stuart; John Lazarchick; Makio Ogawa
Journal:  Exp Hematol       Date:  2009-09-26       Impact factor: 3.084

9.  Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.

Authors:  Gergely Varga; Judit Kiss; Judit Várkonyi; Virág Vas; Péter Farkas; Katalin Pálóczi; Ferenc Uher
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

10.  No telomere shortening in marrow stroma from patients with MDS.

Authors:  A Mario Marcondes; Steven Bair; Peter S Rabinovitch; Ted Gooley; H Joachim Deeg; Rosana Risques
Journal:  Ann Hematol       Date:  2008-12-03       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.